Literature DB >> 7794819

General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect.

E Ciccone1, D Pende, L Nanni, C Di Donato, O Viale, A Beretta, M Vitale, S Sivori, A Moretta, L Moretta.   

Abstract

Some HLA-C alleles have been shown to exert a specific protective effect preventing target cells from lysis by groups of natural killer (NK) clones displaying a defined specificity. In this study, we analyzed whether class I-mediated protection is a more general phenomenon involving all NK cells. First, we utilized two anti-class I mAbs (6A4 of IgG1 isotype and A6-136 of IgM isotype), which had been shown to induce lysis of protected target cells by group 1 and group 2 NK clones. Addition of A6-136 or 6A4 used as F(ab')2 mAb resulted in lysis of protected target cells by all NK clones analyzed. Target cells were represented by a panel of HLA homozygous Epstein-Barr virus-transformed B cell lines (B-EBV) while NK clones were representative of clones displaying different GL183/EB6 surface phenotypes and/or different abilities to lyse allogeneic cells. Unselected NK clones derived from seven different individuals were tested against autologous target cells represented by phytohemagglutinin-induced blasts or B-EBV transformed cell lines. In both instances, addition of a mixture of 6A4 F(ab')2 and A6-136 mAbs resulted in lysis of autologous target cells, thus suggesting that class I molecules prevent lysis of normal cells by self NK cells. We further investigated whether the class I-mediated protection requires the complexed form of class I molecules (composed of alpha chain, beta 2-microglobulin and the antigen peptide) or rather the free alpha chain. Acidic treatment of the C1R (Cw4+) target cells or 81.22 (Cw3+, Cw4+) at pH 2.2 resulted in loss of reactivity with 6A4, A6-136 and W6-32 mAb (known to react with the assembled form of class I molecules) and in the de novo reactivity with L31 mAb (specific for the HLA-C free chain). While the untreated Cw+ C1R cells were resistant to lysis by the Cw4-specific group 1 NK clones, the pH 2.2-treated cells became highly susceptible to lysis by the same clones. These data indicate that, at least for the NK clones analyzed, the protection of target cells requires class I molecules in the complexed form.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794819     DOI: 10.1093/intimm/7.3.393

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  11 in total

Review 1.  The molecular basis of natural killer (NK) cell recognition and function.

Authors:  L Moretta; M C Mingari; D Pende; C Bottino; R Biassoni; A Moretta
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

2.  Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Authors:  Nidale Tarek; Jean-Benoit Le Luduec; Meighan M Gallagher; Junting Zheng; Jeffrey M Venstrom; Elizabeth Chamberlain; Shakeel Modak; Glenn Heller; Bo Dupont; Nai-Kong V Cheung; Katharine C Hsu
Journal:  J Clin Invest       Date:  2012-08-06       Impact factor: 14.808

3.  HLA-F complex without peptide binds to MHC class I protein in the open conformer form.

Authors:  Jodie P Goodridge; Aura Burian; Ni Lee; Daniel E Geraghty
Journal:  J Immunol       Date:  2010-05-05       Impact factor: 5.422

4.  Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors.

Authors:  C Andrew Stewart; Fanny Laugier-Anfossi; Frédéric Vély; Xavier Saulquin; Jenifer Riedmuller; Agnès Tisserant; Laurent Gauthier; François Romagné; Géraldine Ferracci; Fernando A Arosa; Alessandro Moretta; Peter D Sun; Sophie Ugolini; Eric Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

5.  Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.

Authors:  Joanna Baginska; Elodie Viry; Guy Berchem; Aurélie Poli; Muhammad Zaeem Noman; Kris van Moer; Sandrine Medves; Jacques Zimmer; Anaïs Oudin; Simone P Niclou; R Chris Bleackley; Ing Swie Goping; Salem Chouaib; Bassam Janji
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

6.  Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog.

Authors:  C C Leong; T L Chapman; P J Bjorkman; D Formankova; E S Mocarski; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

7.  Uptake of CCR7 by KIR2DS4⁺ NK cells is induced upon recognition of certain HLA-C alleles.

Authors:  Silvia Pesce; Simona Carlomagno; Alessandro Moretta; Simona Sivori; Emanuela Marcenaro
Journal:  J Immunol Res       Date:  2015-04-16       Impact factor: 4.818

8.  Modulation of Human Leukocyte Antigen-C by Human Cytomegalovirus Stimulates KIR2DS1 Recognition by Natural Killer Cells.

Authors:  Kattria van der Ploeg; Chiwen Chang; Martin A Ivarsson; Ashley Moffett; Mark R Wills; John Trowsdale
Journal:  Front Immunol       Date:  2017-03-29       Impact factor: 7.561

9.  Identification of neuroblastoma cell lines with uncommon TAZ+/mesenchymal stromal cell phenotype with strong suppressive activity on natural killer cells.

Authors:  Claudia Canzonetta; Andrea Pelosi; Sabina Di Matteo; Ignazio Caruana; Bruno Azzarone; Irene Veneziani; Nicola Tumino; Paola Vacca; Enrico Munari; Marco Pezzullo; Charles Theuer; Rita De Vito; Vito Pistoia; Luigi Tomao; Franco Locatelli; Lorenzo Moretta
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

10.  Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.

Authors:  Yelei Guo; Beilei Xu; Zhiqiang Wu; Jian Bo; Chuan Tong; Deyun Chen; Jin Wang; Haoyi Wang; Yao Wang; Weidong Han
Journal:  Eur J Immunol       Date:  2021-08-19       Impact factor: 6.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.